Screening for thrombophilia;Labormedizinische aspekte des thrombophilie-screenings

Hamostaseologie

Volumn 28, Issue 3, 2008, Pages 135-140

  Lammers, T ^a   Schambeck, Christian M ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Coagulation diagnostics; Preanalyses; Thrombophilia

Indexed keywords

DIAGNOSTIC TEST; FAMILY HISTORY; GROUPS BY AGE; HUMAN; LABORATORY TEST; REVIEW; SCREENING; THROMBOPHILIA;

HEMATOLOGIC TESTS; HUMANS; MASS SCREENING; THROMBOPHILIA;

EID: 46749141364     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617171     Document Type: Review

References (40)

1. Adcock D, Kressin D, Marlar RA.The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis 1998; 9: 463-470.
2. Alhenc-Gelas M, Reny J-L, Aubry M-L et al. The FXIII Val 34 Leu mutation and the risk of venous thrombosis. Thromb Haemost 2000; 84: 1117-1118.
3. Bathum L, Münster A-M, Nybo M et al. Denaturing High-Performance Liquid Chromatography mutation analysis in patients with reduced protein S levels. Clin Chim Acta 2008; 390: 76-81.
4. Bruhn HD, Schambeck, CM, Hach-Wunderle V Hämostaseologie für die Praxis. Stuttgart: Schattauer 2007; 67-69.
5. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol (Basel) 1957; 17: 237-241.
6. Cooper PC, Hampton KK, Makris M et al. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994; 88: 201-203.
7. Cooper PC, Rezende SM. An overview of methods for detection of factor V Leiden and the prothrombin G20210A mutations. Int J Lab Hem 2007; 29: 153-162.
8. De Laat B, Derksen RH, De Groot PG. High-avidity anti-beta glycoprotein I antibodies highly correlate with thrombosis in contrast to low avidity anti-beta-glycoprotein I antibodies. J Thromb Haemost 2006; 4: 1619-1621.
9. Devreese KM. Evaluation of a new silica clotting time in the diagnosis of lupus anticoagulants. Thromb Res 2007; 120: 427-438.
10. Eichinger S. Globaltest versus Profil: Wird das endogene Thrombinpotential das etablierte Thrombophiliescreening ablösen? J Lab Med 2008, in Druck.
11. Galli M, Luciani D, Bertolini G et al. Anti-beta 2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis int the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
12. Gessoni G, Valverde S. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patiens with venous thrombosis. Blood Coag and Fibrinolysis 2007; 18: 603-610.
13. Goodwin AJ, Rosendaal FR, Kottke-Marchant K et al. A review of the technical, diagnostic and epidemiologic considerations for protein S-Assays. Arch Pathol Lab Med 2002;126: 1349-1366.
14. Gosselin RC, King JH, Janatpur KA et al. Effects of pentasaccharide (Fondaparinux) and direct thrombin inhibtors on coagulation testing. Arch Pathol Lab Med 2004; 128: 1142-1145.
15. Heil W, Grunewald. R, Amend M et al. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med 1998; 36: 459-462.
16. Jennings I, Kitchen S, Cooper P et al. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits. J Thromb Haemost 2003; 1: 1112-1117.
17. Johnson JV, Lowell JL, Badger GJ et al. Effects of oral and transdermal hormonal contraception on vascular risk markers. Obstetr Gyn 2008; 111: 278-284.
18. Koenen RR, Tans G, van Oerle R et al. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102: 1686-1692.
19. Kwok S, Higuchi R. Avoiding false posititves with PCR. Nature 1984: 339: 237-238.
20. Lim W, Crowther M. Antiphospholipid antibodies: a critical review of the literature. Curr Opin Hematol 2007; 14: 494-199.
21. Mackie I, Cooper, P, Kitchen S. Quality assurance issues and interpretation of assays. Semin Hematol 2007; 44: 114-125.
22. Meijer P, Verbruggen W, de Weerd B et al. Identification of determinants of the between-operator variation of the total protein S antigen assay: a collaborative study of the Dutch Working Group on Haemostasis Laboratory Diagnosis. Scand J Clin Lab Invest 2002; 62: 441-450.
23. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
24. Moore GW, Smith MP, Patel Y et al. The Activated Seven Lupus Anticoagulant (ASLA) assay: a new test for lupus anticoagulants. Evidence that some LAs are detectable only in extrinsic pathway assays. Blood Coagul Fibrinolysis 2002; 13: 261-269.
25. Moore GW, Rangarajan S, Savidge F. The Activated Seven Lupus Anticoagulant Assay detects clinically significant antibodies. Clin Appl Thromb Hemost 2007; Sep 25 (epub): 1-6.
26. Moore GW, Savidge GF. Heterogeneity of Russel's viper venom affects the sensitivity of the dilute Russel's viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis 2004; 15: 279-282.
27. Moore GW. Combining Taipan snake venom Time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb J 2007; 5: 12.
28. rd ed.
29. Pellegrino NM, Caccavo D. Variability in anticardioloipin antibody detection: Role of non-specific IgG binding and different microtiter plates. Clin Appl Thromb Haemost 2007; 13: 404-109.
30. Quehenberger P, Handler S, Mannhalter C. Evaluation of a highly specific functional test for the detection of factor V Leiden. Int J Clin Lab Res 2000; 30: 113-117.
31. Schöni R. Quenhenberger P, Wu JR et al. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit® APC-R Factor V Leiden) at two centers in Europe and the USA. Thromb Res 2007; 119: 17-26.
32. Siegert G, Schellong S, Knoepfler R et al. Low molecular weight heparin: a possible cause for higher protein S activity than free protein S concentration. Blood Coagul Fibrinolysis 2000; 11: 747-754.
33. Tomer A, Bar-Lev S, Fleisher S et al. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol 2007; 139: 113-120.
34. Töpfer G, Funke U, Schulze M et al. Determination of coagulation parameters in venous citrated blood, catheter blood and capillary blood: preanalytical problems. J Lab Med 2000; 24: 514-520.
35. Thomas L. Labor und Diagnose. 6. Aufl. Frankfurt/Main: TH-Books 2005; 596-600.
36. Tsuda T, Tsuda H, Yoshimura H et al. Dynamic equilibrium between protein S and C4b binding protein ist important for accurate determination of free protein s antigen. Clin Chem Lab Med 2002; 40: 563-567.
37. Urbanus RT, Derksen RHMW, de Groot PG. Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Reviews 2008; 22: 93-105.
38. Van Cott EM, Ledford-Kraemer M, Meijer P et al. An analysis of North American specialized coagulation laboratory association proficiency testing. Am J Clin Pathol 2005; 123: 778-785.
39. Vester B, Rassmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549-554.
40. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.